Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of cemiplimab plus ISA101b in recurrent or metastatic HPV16-positive oropharyngeal cancer after prior PD-1 inhibitor progression
MOH_2021-05-27_009725Phase 2Not yet recruiting
- Sponsor
- ISA Pharmaceuticals
- Start
- Jan 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cemiplimab and SLP-HPV-01 in oropharyngeal cancer and head and neck squamous cell carcinoma (HNSCC), sponsored by ISA Pharmaceuticals. Planned start Jan 2021; status: not yet recruiting.
02
Drugs
cemiplimabSLP-HPV-01
03
Conditions
oropharyngeal cancerhead and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on MOH_2021-05-27_009725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-05-27_009725.